RxDoctor Payments Data

David Sachar, MD

Gastroenterology · Columbia, SCNPI 1770644478

Payments from drug & device makers

$10,668in general payments, 2019–2025

Across 92 payments — averaging $115.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius Kabi USA, LLC$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • Alcresta Therapeutics, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$837
  • Johnson & Johnson$329
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$5,20349%
  • Speaking & faculty fees$1,60015%
  • Food & beverage$3,76635%
  • Education$991%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,668 in reported general payments places this provider in the 75th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$41,392
Medicare patients
214
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$96,839
CreonLipase/Protease/Amylase22$28,548
LinzessLinaclotide20$19,899
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates90$5,643
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag35$4,180
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C23$3,292
Mercaptopurine24$1,594
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl87$1,297
Omeprazole96$994
Pantoprazole Sodium41$578
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl17$303
Famotidine32$258
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg14$185
Ondansetron Hcl13$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,608$48,44842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →